JP2024512767A5 - - Google Patents

Info

Publication number
JP2024512767A5
JP2024512767A5 JP2023560831A JP2023560831A JP2024512767A5 JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5 JP 2023560831 A JP2023560831 A JP 2023560831A JP 2023560831 A JP2023560831 A JP 2023560831A JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered
alkyl
hydrogen
bonded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023133 external-priority patent/WO2022212894A1/en
Publication of JP2024512767A publication Critical patent/JP2024512767A/ja
Publication of JP2024512767A5 publication Critical patent/JP2024512767A5/ja
Pending legal-status Critical Current

Links

JP2023560831A 2021-04-02 2022-04-01 Rasの阻害方法 Pending JP2024512767A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170292P 2021-04-02 2021-04-02
US63/170,292 2021-04-02
US202163192843P 2021-05-25 2021-05-25
US63/192,843 2021-05-25
PCT/US2022/023133 WO2022212894A1 (en) 2021-04-02 2022-04-01 Methods for inhibiting ras

Publications (2)

Publication Number Publication Date
JP2024512767A JP2024512767A (ja) 2024-03-19
JP2024512767A5 true JP2024512767A5 (cg-RX-API-DMAC7.html) 2025-04-08

Family

ID=83456876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560831A Pending JP2024512767A (ja) 2021-04-02 2022-04-01 Rasの阻害方法

Country Status (12)

Country Link
US (1) US20240108630A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320143A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512767A (cg-RX-API-DMAC7.html)
KR (1) KR20240004436A (cg-RX-API-DMAC7.html)
AU (1) AU2022249177A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214155A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230500A (cg-RX-API-DMAC7.html)
IL (1) IL307396A (cg-RX-API-DMAC7.html)
MX (1) MX2023011608A (cg-RX-API-DMAC7.html)
TW (1) TW202308632A (cg-RX-API-DMAC7.html)
WO (1) WO2022212894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023232776A1 (en) * 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
CN117720555B (zh) * 2022-09-19 2026-05-05 杭州阿诺生物医药科技有限公司 一种制备kras抑制剂化合物的中间体及其合成方法
CN117903169A (zh) * 2022-09-19 2024-04-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
CN118047799A (zh) * 2022-11-16 2024-05-17 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN117534684A (zh) * 2022-11-29 2024-02-09 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
EP4661887A1 (en) * 2023-02-06 2025-12-17 Bicara Therapeutics Inc. Combination therapy and related methods
PE20252395A1 (es) 2023-02-14 2025-10-10 Hoffmann La Roche Compuestos triciclicos para el tratamiento de cancer
WO2024187174A2 (en) * 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
CN121487738A (zh) * 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
CN121843944A (zh) * 2023-09-06 2026-04-10 劲方医药科技(上海)股份有限公司 大环化合物及其抗体-药物偶联物
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025087431A1 (zh) * 2023-10-27 2025-05-01 贝达药业股份有限公司 泛-kras抑制剂及其在医药上的应用
WO2025093625A1 (en) * 2023-11-01 2025-05-08 F. Hoffmann-La Roche Ag Macrocycle compounds for the treatment of cancer
IL328671A (en) * 2023-12-08 2026-07-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Macrocyclic compound containing an amide substituent
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025193628A2 (en) * 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025252241A1 (zh) * 2024-06-07 2025-12-11 杭州和正医药有限公司 一种大环衍生物及其用途
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015745A1 (en) * 2024-07-11 2026-01-15 Treeline Biosciences, Inc. Macrocyclic ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
IL317393A (en) * 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses
CN121471132A (zh) * 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
MX2022005359A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (en) * 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) * 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy

Similar Documents

Publication Publication Date Title
JP2024521774A5 (cg-RX-API-DMAC7.html)
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
JP2026041825A (ja) 固体形態
Chiyanzu et al. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives
ES2387270T3 (es) El archivo contiene la información técnica propuesta después de la presentación de la solicitud y no se incluye en esta especificación
DK2924034T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
Patel et al. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle
JP2024521920A5 (cg-RX-API-DMAC7.html)
JP7274765B2 (ja) フェニルトリアゾールmll1-wdr5タンパク質間相互作用阻害剤
JP2018530594A (ja) 新規な化合物であるyap/taz−tead相互作用阻害剤、および悪性中皮腫の治療でのその使用
CN119528810A (zh) 喹啉类化合物及其应用
WO2017167182A1 (zh) 一种选择性的c-kit激酶抑制剂
JP2010512358A (ja) スルホンアミドならびに薬剤としてのその使用
CN105579449A (zh) 新的用作nampt抑制剂的吡啶基氧基乙酰基四氢异喹啉化合物
CN108101890A (zh) N-磺酰基吡咯衍生物
TW200301698A (en) Acridone inhibitors of IMPDH enzyme
TW202313048A (zh) 組合療法
KR20070112400A (ko) 신규의 hsp90 저해제
BR122022005149B1 (pt) Compostos com atividade anticâncer, composição farmacêutica que os compreende e seus usos
Ghomashi et al. Recent advances in biological active sulfonamide based hybrid compounds part A: Two-component sulfonamide hybrids
JP2012512887A5 (cg-RX-API-DMAC7.html)
JP2009537546A5 (cg-RX-API-DMAC7.html)
ES2300775T3 (es) Furazanobencimidazoles.
TW200812970A (en) Inhibitors of AKT (protein kinase B)
CN103193691A (zh) 磺胺类化合物、药物组合物及其制法和应用